Pancreatic Cancer UK’s Early Diagnosis Research Alliance: Providing evidence for implementation
Understanding the best setting within the NHS for a potential new blood test for the early diagnosis of Pancreatic Cancer
About the research
Pancreatic Cancer UK’s Early Diagnosis Research Alliance supports dozens of the brightest research minds from institutions across the UK, to once and for all, meaningfully drive down the time to diagnosis for people with pancreatic cancer. They will do this through the close collaboration between four key specialists areas in the delivery of early diagnosis. By sharing information and knowledge and coordinating efforts, the different work areas will be enhanced by one another and at the same time minimise duplication and waste.
This opportunity relates to one of the four key specialist areas described above which focuses on providing evidence for implementation. The overall goal of this work package is to talk to various stakeholders, including people affected by pancreatic cancer, clinicians, GPs, surgeons, health professionals and policy makers, to identify the best potential setting within the NHS for a new blood test for early diagnosis of pancreatic cancer. These findings will ultimately help inform a health economic model that will determine the cost-effectiveness of the new test if it was to be introduced to the UK NHS.
Type of opportunity
Members of the Research Involvement Network are asked to take part in a consensus meeting that will last up to 2 hours. One meeting will be held in London on 27th April from 2pm - 4pm and the other will be held in Glasgow (date tbc). Participants will include up to 15 people with various backgrounds ranging from clinicians, health professionals and policymakers to people affected by pancreatic cancer.
The overall goal is to reach a consensus within the group for the potential setting within the NHS pathway for a new blood test for the early diagnosis of pancreatic cancer.
Therefore, the meeting will involve 3 stages:
Stage 1: A brief overview of the study and previous research will be presented to the participants
Stage 2: The participants will be asked to provide insights on diagrams highlighting the different steps involved in diagnosing, and or, treating pancreatic cancer based on their own or their loved ones experience with pancreatic cancer. As part of a group discussion a consensus will be reached on the best place in the NHS diagnosis pathway for a new blood biomarker test for the early detection of pancreatic cancer.
Stage 3: Finally, the participants will be asked to complete a short questionnaire based on their own experiences to identify key players involved in the uptake of the new blood biomarker test.
Who is conducting the research?
Researchers from both Imperial College London (Dr Melody Ni & Dr Anna McLister) and Strathclyde University (Dr Robert Van Der Meer & Dr Nicola Irvine) will be conducting the research. The study has been reviewed by the clinical audit team as a service evaluation at the Imperial College Healthcare NHS Trust.
When is the deadline for this opportunity?
Please contact us with your expressions of interest by no later than the 13th March 2020.
The London meeting is due to take place 2pm - 4pm on the 27th April at St Mary’s Hospital in Paddington.
The Glasgow meeting is due to take place in May at the University of Strathclyde campus in the centre of Glasgow (date tbc with all attendees).
Who can take up this opportunity?
Anyone who is over the age of 18
Anyone who is a patient representative or carer of someone who has been diagnosed with pancreatic cancer (PDACs, or PNETS) and is willing to discuss their experience with the NHS diagnosis pathway.
How will the study benefit people affected by pancreatic cancer?
The information that you provide will help support the research behind the development of a future blood test that could potentially help diagnose more patients with pancreatic cancer at a stage when they can undergo treatment and potentially live longer.
What out of pocket expenses will be paid?
Participants will be reimbursed up to £100 for their travel expenses for the day and will also be given Amazon vouchers for their time.
What next/who to contact:
If you would be interested in taking part in either the London or Scotland consensus meeting then please contact email@example.com with a short description of your experience of pancreatic cancer and details of where you are based and which of the meetings you would like to attend.